论文部分内容阅读
目的探讨恩替卡韦治疗乙肝相关性肾炎(HBV-GN)的临床效果。方法 25例患者在给予甘利欣、门冬氨酸钾等基础治疗上,给予恩替卡韦口服,3个月为1疗程,2个疗程后观察治疗前后患者的临床症状和体征,肝肾功能、HBV-DNA、24h尿蛋白定量等变化。结果 1个疗程后,总有效率为84%;2个疗程后,总有效率为92%;治疗后6个月血清谷丙转氨酶、血清白蛋白、24h尿蛋白定量与治疗前比较差异均有统计学意义(P<0.01),但血清肌酐治疗前后无明显变化。结论恩替卡韦治疗乙肝相关性肾炎疗效确切。
Objective To investigate the clinical efficacy of entecavir in the treatment of hepatitis B-related nephritis (HBV-GN). Methods 25 patients received oral administration of entecavir on the basis of glycyrrhizin and potassium aspartate for 3 months for 1 course of treatment. After 2 courses of treatment, the clinical symptoms and signs, liver and kidney function, HBV- DNA, 24h urinary protein and other quantitative changes. Results After a course of treatment, the total effective rate was 84%. After 2 courses of treatment, the total effective rate was 92%. After 6 months of treatment, the levels of serum ALT, serum albumin and 24-hour urine protein were significantly different from those before treatment Statistical significance (P <0.01), but serum creatinine before and after treatment did not change significantly. Conclusion Entecavir treatment of hepatitis B-related nephritis curative effect.